Operator
Hi there, and welcome to Ipsen’s Convention Name and Webcast on Q3 2025 Outcomes.
I will now hand you over to David Loew, Ipsen’s CEO.
David Loew
MD, CEO & Director
Thanks, and hiya, everybody. I am delighted to welcome you this afternoon to our year-to-date and third quarter gross sales presentation, which may also be discovered on ipsen.com. It is a pleasure to take you thru the progress we’re making this yr.
Please flip to Slide 2. Please observe of our forward-looking assertion, which outlines the routine dangers and uncertainties contained inside this presentation. Additionally, all of my feedback on development might be based mostly on fixed trade charges.
Please flip to Slide 3. I’ll take you thru our transient presentation, after which our CFO, Aymeric Le Chatelier; and our Head of R&D, Christelle Huguet, will be a part of me to reply your questions.
Let’s start by having a look at right now’s highlights. Please flip to Slide 4. In the present day’s highlights illustrate how we’re persevering with to ship robust development. Whole gross sales grew by 13.7% this quarter and by 12.1% within the first 9 months. We’re very happy to see a powerful efficiency of our portfolio outdoors Somatuline, which grew by 12.3% within the 9-month interval. Primarily based on this continued stable momentum and
